November is Lung Cancer Awareness Month
JOIN WITH AACR TO FIND BETTER WAYS TO PREVENT AND TREAT LUNG CANCER
Lung cancer is the most common cause of cancer death in the United States for both men and women. About 63,040 men and 61,950 women are estimated to die from lung cancer in 2026.
According to estimates by the National Cancer Institute, 229,410 patients are expected to receive a diagnosis of lung or bronchus cancer in the United States in 2026. The estimated five-year relative survival rate is 29.5%.
Smoking is the most common cause of lung cancer in the United States. Cigarette smoking causes about 80% of lung cancer deaths, according to experts. Other risk factors for lung cancer include being exposed to secondhand smoke; having a family history of lung cancer; living with HIV; being treated with radiation therapy to the breast or chest; exposure to asbestos, arsenic, chromium, beryllium, or nickel in the workplace; and exposure to radon. When smoking is combined with other risk factors, the risk of lung cancer increases.
Forms of lung cancer
There are two main forms of lung cancer—small cell lung cancer and non-small cell lung cancer.
Non-small cell lung cancer (NSCLC) is the more common form of the disease, accounting for over 85% of diagnosed cases. The most common subtypes of NSCLC are:
- squamous cell carcinoma, which begins in the thin, flat squamous cells;
- large cell carcinoma; and
- adenocarcinoma.
Adenocarcinoma is the most common subtype of NSCLC and patients with this type of lung cancer have a relative five-year survival rate overall of about 38% across all stages.
About 12% of all lung cancer cases are small cell lung cancer (SCLC). This is a fast-growing, aggressive disease with poor outcomes. Unfortunately, most patients with SCLC are diagnosed with extensive-stage disease. That means it has spread beyond the lung and the area between the lungs to other lymph nodes or other parts of the body. Overall, 5% to 10% of patients with SCLC are alive five years after diagnosis.
Screening recommendation
Current guidelines recommend annual screening with low-dose CT scan in adults aged 50 to 80 who have a 20-pack-year smoking history and currently smoke or stopped smoking within the past 15 years. Specifically, a pack-year is the number of packs of cigarettes smoked per day times the number of years smoking. Thus, someone who smoked one pack per day for 20 years has a 20-pack-year smoking history.
Lung Cancer Survivor Stories
At 33 years old, Sydney Barned, MD was focused on her career as a physician when she started to experience persistent wheezing during the first few months of residency. She was a lifelong athlete who trained in ballet, swam, ran track, and had never smoked, but tests would later reveal she had stage 4 NSCLC with an ALK gene rearrangement. This genetic alteration in her tumor meant she could be treated with a type of targeted therapy known as an ALK inhibitor. Nearly a decade after her diagnosis, Sydney’s disease remains well controlled with ALK-targeted therapy. Read her story in the AACR Cancer Progress Report 2026.
During a routine physical examination in June 2020, James Gregory (Greg) Cisneros casually mentioned to his physician that he had a “spongy” feeling while breathing. The comment prompted a chest X-ray, which revealed a mass in his lower right lung. While he had the tumor surgically removed in September 2020, the cancer would return in both of his lungs less than a year later. This time, a biopsy of his tumor showed a HER2 gene mutation, so his physician referred him to a clinical trial investigating a targeted therapy designed to block abnormal HER2 signaling. More than three and a half years after starting the trial, Greg’s disease is under control. Read his story in the AACR Cancer Progress Report 2026.
action on smoking and lung cancer
Because of the potential impact of cigarette smoking and e-cigarette usage on cancer incidence and mortality, AACR supports necessary measures to reduce these behaviors. This includes advocating for a nicotine product standard that would effectively cap the amount of nicotine allowed in combustible cigarettes. The AACR Tobacco Products and Cancer Subcommittee published a paper in the AACR journal Clinical Cancer Research detailing the immense benefit such a change would have on public health. Learn more on the AACR blog Cancer Research Catalyst.
The good news is that smoking prevalence in the United States has never been lower. After peaking in 1965 at 42.4%, the U.S. smoking rate has fallen to only about 9.9% of all U.S. adults, according to the Centers for Disease Control and Prevention (CDC). Lung cancer incidence has also followed a downward trend (albeit a more recent one), peaking in the United States in 1992 at 66.4 cases per 100,000 but falling to 43.4 per 100,000 as of 2023, according to the NCI. Learn more about the latest smoking and vaping rates on Cancer Research Catalyst.
More on Lung Cancer
Some people turn to e-cigarettes as a way to quit smoking, but a recent study found that vaping also exposes people to harmful chemicals, such as benzene, that can compromise their health. The study also found that people who vaped had elevated molecular markers indicating genetic changes and inflammation, which are often implicated in cancer development. Learn more in AACR’s patient magazine Cancer Today.
Shira Kupperman Boehler, who never smoked a cigarette in her life but was diagnosed with lung cancer when she was 43, wrote a book detailing her experience and the case for expanding lung cancer screening to people 40 and older and others who may be at high risk for the disease. Read an interview with her in Cancer Today.
As researchers continue to explore why lung cancer develops in never-smokers, one recent study found that carriers of an inherited mutation in epidermal growth factor receptor, or EGFR, known as T790M, had a 25-fold increased risk of lung cancer, and those who never smoked and had the mutation were more than 60 times more likely to develop lung cancer than noncarriers. Learn more about the study on Cancer Research Catalyst.
At the AACR Annual Meeting 2026, researchers presented results from a clinical trial exploring the use of the KRAS G12C inhibitor elisrasib to treat NSCLC. Read about the results in Cancer Today.
Another study at the AACR Annual Meeting 2026 found that exposure to wildfire smoke was associated with a significantly higher risk of developing lung, colorectal, breast, bladder, and blood cancers. Learn more about the study and rise of wildfires in the United States on Cancer Research Catalyst.
In October 2026, Pope Leo XIV was diagnosed with lung adenocarcinoma, but because the cancer was detected early he was able to have it removed without the need for further treatment. His case is just one example of how far we’ve come in our understanding of preventing and treating lung cancer, thanks to cancer research. Cancer Research Catalyst provided an overview of some of the remarkable progress made against lung cancer to this point.
How AACR Supports LunG Cancer Research
Lung Cancer Task Force
The AACR Lung Cancer Task Force brings together leading experts committed to advancing the field of lung cancer research. Led by the current chair, Charles Swanton, MBPhD, FAACR, of the Francis Crick Institute and UCL Cancer Institute in the United Kingdom, this group is working to accelerate progress and improve outcomes for patients affected by lung cancer.
major Conference
The AACR Conference: Redefining Lung Cancer: From Mechanistic Biology to Emerging and AI‑Driven Therapies will be held January 14-17, 2027, in San Diego, California. The conference is held in association with the AACR Lung Cancer Task Force.
Grants for Lung Cancer Research
The AACR is active in supporting lung cancer research. Learn more about grant-supported research projects:
- Three of the AACR Trailblazer Research Grants for Early-stage Investigators awarded in 2026 went to researchers focused on lung cancer. Karen Dixon, PhD, of the University of Basel, is looking into how neural signals shape antitumor responses in lung cancer. Theodore L. Roth, MD, PhD, of Stanford University, developed a predictive diagnostic testing method to explore various cellular immunotherapy enhancements that could potentially improve treatments for lung cancer. Natalie Vokes, MD, Mphil, of The University of Texas MD Anderson Cancer Center, is investigating how CDKN2A/MTAP loss in NSCLC shapes tumor-immune interactions and treatment response.
- In 2026, Hyunwoo Kwon, MD, PhD, of the Dana-Farber Cancer Institute, received the AACR Non-Small Cell Lung Cancer Research Fellowship to study epigenetic plasticity and DLL3-targeting strategies for certain forms of NSCLC.
- In 2025, Yoojeong Seo, PhD, of The University of Texas MD Anderson Cancer Center, received the Bosarge Family Foundation-Waun Ki Hong Scholar Award for Regenerative Cancer Medicine. She is investigating ways to manipulate cell plasticity to alleviate radiation-induced pulmonary fibrosis, which is a severe complication of thoracic radiation therapy.
- In 2025, Alice Tzeng, MD, PhD, of the Dana-Farber Cancer Institute, received the AACR-ALK Positive Lung Cancer Research Fellowship to assess the role epigenetic changes play in developing resistance to the ALK inhibitor lorlatinib (Lorbrena) and to test pairing lorlatinib with epigenetic modulators to overcome treatment resistance.
- Pedro Torres-Ayuso, PhD, of Temple University, and Lisa Derosa, MD, PhD, of Gustave Roussy, were named the 2025 recipients of the AACR Career Development Awards in Lung Cancer Research. Torres-Ayuso is investigating the potential of inhibiting the TNIK signaling network to enhance treatment efficacy in lung squamous cell carcinoma. Derosa is exploring the role of the gut microbiota in shaping responses to immune checkpoint inhibitors in NSCLC.
for more information
For more information, including guidance on prevention, screening, and treatment, please see our page on lung cancer.
